Humacyte (HUMA) Profit After Tax (2020 - 2026)
Humacyte (HUMA) posted quarterly Profit After Tax of -$17.6 million for Q1 2026, down 145.02% year-over-year from $39.1 million in Q1 2025, and up 28.97% quarter-over-quarter from -$24.8 million in Q4 2025.
Humacyte (HUMA) Profit After Tax (2020 - 2026) Analysis & Trends
Humacyte (HUMA) has reported Profit After Tax for 7 consecutive years, with -$17.6 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Profit After Tax fell 145.02% year-over-year to -$17.6 million; the TTM figure through Mar 2026 stood at -$97.6 million (down 25.65% YoY), while the FY2025 annual figure was -$40.8 million, up 72.54% from the prior year.
- Profit After Tax climbed to -$17.6 million in Q1 2026 per HUMA's latest filing, from -$24.8 million in the prior quarter.
- Across five years, Profit After Tax topped out at $39.1 million in Q1 2025 and bottomed at -$56.7 million in Q2 2024.
- Historically, Profit After Tax has averaged -$19.4 million across 5 years, with a median of -$24.8 million in 2025.
- Annual changes were most pronounced in 2022 — Profit After Tax jumped 314.37% — and 2023, when it sank 574.89%.
- Humacyte's Profit After Tax stood at -$3.7 million in 2022, then tumbled by 574.89% to -$25.1 million in 2023, then grew by 16.59% to -$20.9 million in 2024, then declined by 18.45% to -$24.8 million in 2025, then climbed by 28.97% to -$17.6 million in 2026.
- Business Quant data shows HUMA's Profit After Tax at -$17.6 million in Q1 2026, -$24.8 million in Q4 2025, and -$17.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 472.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -355.03 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -16.62 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Humacyte | 150.77 Mn | 150.77 Mn | -825,000.00 | -36.80 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -36.80 Mn |
| Mar 31, 2026 | -17.62 Mn |
| Dec 31, 2025 | -24.80 Mn |
| Sep 30, 2025 | -17.51 Mn |
| Jun 30, 2025 | -37.66 Mn |
| Mar 31, 2025 | 39.14 Mn |
| Dec 31, 2024 | -20.94 Mn |
| Sep 30, 2024 | -39.20 Mn |
| Jun 30, 2024 | -56.66 Mn |
| Mar 31, 2024 | -31.90 Mn |
| Dec 31, 2023 | -25.11 Mn |
| Sep 30, 2023 | -26.00 Mn |
| Jun 30, 2023 | -22.71 Mn |
| Mar 31, 2023 | -36.97 Mn |
| Dec 31, 2022 | -3.72 Mn |
| Sep 30, 2022 | -25.28 Mn |
| Jun 30, 2022 | 36.87 Mn |
| Mar 31, 2022 | -19.83 Mn |
| Dec 31, 2021 | 42.59 Mn |
| Sep 30, 2021 | -31.56 Mn |